Blog
RSS FeedPosted by Michael Wonder on 31 Oct 2019
Parallel distributed or parallel imported Maviret and Viekirax remain in high cost protection
28 October 2019 - TLV has reconsidered the subsidy for parallel distributed or parallel imported Maviret and Viekirax and decided ...
Posted by Michael Wonder on 23 Oct 2019
The district court rejected an appeal against Darzalex
21 October 2019 - TLV's decision to reject the grant application for Darzalex was appealed to the Administrative Court in ...
Posted by Michael Wonder on 08 Jul 2019
Withdrawals from the drug benefits - August 2019
8 July 2019 - Etalpha 80 mg & 100 capsules, Leflunomide medac 15 mg & 30 tablets and Maviret 100 mg ...
Posted by Michael Wonder on 03 Jul 2019
Gefitinib in new exchange group
28 June 2019 - As of June, gefitinib is included as an exchange group on the list of period goods. ...
Posted by Michael Wonder on 03 Jul 2019
Joint evaluation report of sotagliflozin (Zynquista)
28 June 2019 - TLV, together with the corresponding authorities in the Netherlands, ZIN, and in Ireland, NCPE, have written ...
Posted by Michael Wonder on 25 Jun 2019
Health economic assessment of Kymriah in diffuse large B-cell lymphoma
20 June 2019 - TLV has produced a health economic knowledge base for county councils for CAR-T cell treatment Kymriah ...
Posted by Michael Wonder on 19 Jun 2019
TLV does not extend Hemlibra's current subsidy
18 June 2019 - Hemlibra has been included in the high-cost protection since autumn 2018 for the treatment of patients ...
Posted by Michael Wonder on 13 Jun 2019
Review of Rotarix
12 June 2019 - TLV has decided to initiate a review of the drug Rotarix due to the Government's decision ...
Posted by Michael Wonder on 13 Jun 2019
TLV publishes first joint report within the FINOSE co-operation
11 June 2019 - FINOSE is a collaboration between the HTA authorities, the pharmaceutical company Fimea (Finland), the Norwegian Medicines Agency, ...
Posted by Michael Wonder on 30 May 2019
Health economic assessment of Luxturna in the treatment of visual impairment caused by hereditary eye disease
29 May 2019 - TLV has produced a health economic knowledge base for the region for the drug Luxturna (voretigene ...
Posted by Michael Wonder on 30 May 2019
More patients get access to medicines within the high-cost protection
29 May 2019 - From June 2 next year, patients who obtain prescription drugs at pharmacies will be able to ...
Posted by Michael Wonder on 27 May 2019
Health economic assessment of Opdivo in combination with Yervoy for the first-line treatment of patients with renal cell carcinoma
27 May 2019 - TLV has produced a health economic knowledge base for the regions of the drug Opdivo (nivolumab) in ...
Posted by Michael Wonder on 23 May 2019
Health economic assessment of Tegsedi in hereditary transthyretin amyloidosis
17 May 2019 - TLV has produced a health economic knowledge base for the regions for Tegsedi (inotersen) that treat hereditary ...
Posted by Michael Wonder on 10 Jul 2018
Time to entry for new cancer medicines: from European Union wide marketing authorisation to patient access in Belgium, Estonia, Scotland, and Sweden
10 July 2018 - This study quantified the median time from European Union wide approval to first use for a ...
Posted by Michael Wonder on 19 Jun 2018
Vertex reaches agreement in Sweden for reimbursement of Orkambi
18 June 2018 - Vertex Pharmaceuticals announced that Orkambi (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic ...